Revolutionizing proof-of-concept results have emerged in transplantation, allowing complete immunosuppression withdrawal long-term in kidney transplant patients. Planned studies aim at enabling safe bone marrow transplantations across HLA-barriers.
Anti-CD2 as induction and rejection treatment
The data outlined below has been generated in Phase I clinical trials of the parent rat monoclonal anti-CD2, named BTI-322, the humanization of which constitutes Siplizumab. BTI-322 has the same specificity as Siplizumab, differing only in its non-humanized framework. These proof-of-concept studies show encouraging safety and efficacy results when using BTI-322, compared to standard of care alone, as induction and rejection treatment in transplantation.